Indication
acute graft-versus-host disease
3 clinical trials
4 products
Product
EQ001Clinical trial
A Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of EQ001 in Subjects With Newly Diagnosed Acute Graft Versus Host DiseaseStatus: Completed, Estimated PCD: 2022-11-21
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Itolizumab in Combination With Corticosteroids for the Initial Treatment of Acute Graft Versus Host DiseaseStatus: Recruiting, Estimated PCD: 2024-07-01
Product
ItolizumabClinical trial
Ruxolitinib in Combination With Corticosteroid as First Line Therapy for the Treatment of High Risk Acute Graft-Versus-Host DiseaseStatus: Completed, Estimated PCD: 2022-08-01
Product
RuxolitinibProduct
Corticosteroid